Aktienanalyse zu Cencora Inc (COR)CORCencora Inc

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

Cencora Inc is a good buy right now due to its current price of $323.85, which is below the average analyst price target of $347.4, suggesting a potential upside of about 7.3%. Additionally, the forward P/E ratio of 15.70 indicates that the stock is relatively undervalued compared to its earnings potential. The recent hedge fund buying activity has increased by 2472.49%, reflecting strong institutional interest, which is a positive signal for long-term investors. However, the RSI is at 74.01, indicating that the stock may be overbought in the short term, which could lead to volatility.

15 analysts cover COR: 7 rate it Buy, 8 Hold and 0 Sell. The average price target is 415.38.